Background {#Sec1}
==========

The prevalence of chronic kidney disease (CKD) is estimated to be 10--15% worldwide \[[@CR1], [@CR2]\]. Therefore, it is currently recognized as a world health concern with evidence that CKD patients have an increased risk of not only cardiovascular diseases, but also all-cause mortality \[[@CR3], [@CR4]\]. In clinical settings, CKD occurs in the elderly and patients with chronic diseases that cause renal damage, such as chronic glomerular nephritis, hypertension, and diabetes mellitus \[[@CR5]--[@CR7]\]. On the other hand, acute kidney injury (AKI) is defined as an abrupt decrease in renal function, and most patients should recover to their baseline level after AKI. However, recent studies have revealed that a significant number of AKI patients eventually develop CKD \[[@CR8]--[@CR10]\], so called "AKI to CKD transition." Thus, AKI has attracted attention as a novel risk factor of CKD.

Pathologically, interstitial fibrosis and inflammation are common features in CKD patients regardless of primary disease \[[@CR11], [@CR12]\]. Although ischemia-reperfusion injury (IRI) is a well-established rodent model of AKI, progression of renal fibrosis and inflammation are also observed in the kidney after IRI \[[@CR13]\]. According to previous studies, several pathological mechanisms, such as hypoxia, microvascular rarefaction, inflammation, transforming growth factor (TGF)-β1 production, and epithelial-mesenchymal transition (EMT), reportedly participate in AKI to CKD transition \[[@CR14]--[@CR16]\]. However, there are currently no effective therapies to prevent AKI to CKD progression.

Some studies have reported that the administration of mesenchymal stem cells (MSCs) exerts beneficial effects against various diseases such as heart disease \[[@CR17]\], stroke \[[@CR18]\], and autoimmune disease \[[@CR19]\]. MSCs were previously considered to promote the regeneration of injured tissue by their capacity to differentiate into multiple tissue types \[[@CR20], [@CR21]\]. However, rather than differentiating, paracrine activities are likely implicated in the therapeutic effects of MSCs \[[@CR22], [@CR23]\]. Notably, recent studies have reported that hypoxia-preconditioned MSCs intensify their paracrine abilities \[[@CR24], [@CR25]\]. These findings led us to the hypothesis that MSCs cultured under 1% O~2~ conditions (1%O~2~ MSCs) suppress IRI-induced renal fibrosis and inflammation more strongly than MSCs cultured under normoxic conditions (21%O~2~ MSCs).

In this study, using rat- and human-derived bone marrow MSCs, we show that 1%O~2~ MSCs ameliorate renal fibrosis and inflammation in vivo and in vitro. We also show that vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and prostaglandin E2 (PGE2) increase in medium of 1%O~2~ MSCs compared with that of 21%O~2~ MSCs. In addition, we show that inhibition of VEGF suppresses HGF secretion and the anti-fibrotic effect of 1%O~2~ MSCs. These findings suggest that the administration of hypoxia-preconditioned MSCs may be a candidate therapy to prevent renal fibrosis and inflammation after AKI.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

Male Sprague-Dawley (SD) rats (6 and 8 weeks old) were purchased from Charles River Laboratories Japan (Yokohama, Japan). The rats at 6 weeks of age were used to collect bone marrow, and rats at 8 weeks were used to induce IRI. Male CAG-enhanced green fluorescent protein (EGFP)-transgenic SD rats (6 weeks old) were purchased from Japan SLC (Shizuoka, Japan) to collect bone marrow. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Hiroshima University (Hiroshima, Japan) (permit number, A16-83) and conducted in accordance with the *Guide for the Care and Use of Laboratory Animals*, *8th ed*, 2010 (National Institutes of Health, Bethesda, MD, USA).

Preparation of MSCs {#Sec4}
-------------------

According to previously described methods \[[@CR26]\], bone marrow was collected from SD and CAG-EGFP-transgenic SD rats and cultured in standard culture medium consisting of DMEM (Sigma-Aldrich, St. Louis, MO, USA) with 10% FBS (Sigma-Aldrich). Cells were passaged four times and used as rat MSCs for transplantation. Human MSCs from bone marrow were purchased from Riken BRC (Ibaraki, Japan). These cells were also cultured in DMEM containing 10% FBS.

Hypoxic preconditioning {#Sec5}
-----------------------

To perform hypoxic preconditioning, MSCs were cultured in DMEM with 10% FBS. At 80% confluence, fresh complete medium was added and hypoxic preconditioning was performed with a Modular Incubator Chamber (MIC 101) (Billups-Rothenberg, San Diego, CA, USA). The cells were incubated in hypoxic conditions (1% O~2~) for 24 h.

Experimental animal model {#Sec6}
-------------------------

Renal IRI was performed by transiently clamping the unilateral renal artery. Rats were anesthetized by an intraperitoneal injection of three types of mixed anesthetic agents: medetomidine, midazolam, and butorphanol. After a laparotomy was performed, the left kidney was exposed. Then, the renal pedicle was clamped by atraumatic vascular clamps for 1 h, followed by reperfusion on a heating blanket. After reperfusion, MSCs (5 × 10^5^ cells/rat) in 0.2 ml PBS were injected through the abdominal aorta clamped above and below the left renal artery bifurcation. At 7 or 21 days post-injection, the rats were sacrificed and their kidneys were collected.

Western blot analysis {#Sec7}
---------------------

Sample collection and western blotting were performed according to previously described methods \[[@CR26]\]. Mouse monoclonal anti-α-SMA antibody (Sigma-Aldrich), mouse monoclonal anti-TGF-β1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-GAPDH antibody (Sigma-Aldrich), rabbit monoclonal anti-p-Smad2 antibody (Cell Signaling Technology, Danvers, MA, USA), mouse monoclonal anti-Smad2 antibody (Cell Signaling Technology), and mouse monoclonal anti-α-Tubulin antibody (Sigma-Aldrich) were used as primary antibodies. Horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (Dako, Glostrup, Denmark) or goat anti-mouse immunoglobulin G (Dako) was used as secondary antibodies. SuperSignal West Dura or the Pico system (Thermo Fisher Scientific, Rockford, IL, USA) were used to detect signals. The intensity of each band was measured by ImageJ software (version 1.47v; National Institutes of Health) and normalized to the level of either GAPDH or α-tubulin.

Immunohistochemistry analysis {#Sec8}
-----------------------------

Immunohistochemical staining was performed according to previously described methods \[[@CR26]\]. The following primary antibodies were used: mouse monoclonal anti-α-SMA antibody (Sigma-Aldrich), rabbit polyclonal anti-collagen type I antibody (Abcam, Cambridge, UK), rabbit polyclonal anti-collagen type III antibody (Abcam), rabbit polyclonal anti-CD3 antibody (Dako), rabbit polyclonal anti-CD68 antibody (Abcam), rabbit monoclonal anti-CD163 antibody (Abcam), and mouse monoclonal anti-EGFP antibody (Takara Bio, Shiga, Japan). CD3-, CD68-, and CD163-positive cells and positive areas for α-SMA and collagen type I and III staining were assessed using ImageJ software by examination of five randomly selected fields (× 100) of the cortex.

Immunohistochemistry analysis (double immunostaining) {#Sec9}
-----------------------------------------------------

Sections of formalin-fixed, paraffin-embedded tissues (4 μm thick) were de-paraffinized, subjected to heat-mediated antigen retrieval in EDTA buffer (pH 9.0) at 98 °C for 40 min, and then blocked in 2.5% normal horse serum (ImmPRESS Horse Anti-Rabbit IgG Polymer kit; Vector Laboratories, Riverside, CA, USA) at room temperature for 20 min. They were incubated with anti-CD163 antibody (Abcam) overnight at 4 °C, followed by incubation with the appropriate secondary antibody (ImmPRESS Horse Anti-Rabbit IgG Polymer kit; Vector Laboratories) at room temperature for 30 min, and then incubated with 3,3′-diaminobenzidine (Sigma-Aldrich) at room temperature for 5 min. After that, they were heated again in EDTA buffer in the same way. They were then blocked, followed by incubation with anti-CD68 antibody (Abcam) and the secondary antibody in the same way, and next incubated with working solution prepared with Vector SG Peroxidase (HRP) Substrate Kit (Vector Laboratories) at room temperature for 5 min.

Histological analysis {#Sec10}
---------------------

Sections of formalin-fixed, paraffin-embedded tissues (2 μm thick) were stained with hematoxylin and eosin (HE), Masson trichrome, and Sirius red to assess histological injury and fibrosis. The areas of interstitial fibrosis were assessed using Lumina Vision (Mitani, Osaka, Japan) by examining five randomly selected fields (× 100) of the cortex.

MSC labeling {#Sec11}
------------

Human MSCs were labeled with CellTracker CM-DiI (Thermo Fisher Scientific) before injection, following the manufacturer's protocols.

Flow cytometric analysis {#Sec12}
------------------------

Flow cytometric analysis was performed according to previously described methods \[[@CR26]\]. The following antibodies were used: anti-human CD29 IgG antibody (BioLegend, San Diego, CA, USA), anti-human CD44 IgG antibody (BioLegend), anti-human CD73 IgG antibody (BioLegend), anti-human CD90 IgG antibody (BioLegend), anti-human CD11b IgG antibody (BioLegend), anti-human CD34 IgG antibody (BioLegend), anti-human CD45 IgG antibody (BioLegend), anti-human HLA-A,B,C IgG antibody (BioLegend), and anti-human HLA-DR IgG antibody (BioLegend). The stained MSCs were analyzed using a BD FACSVerse (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Data were assessed by FlowJo software (FlowJo, LLC; Ashland, OR, USA).

Preparation of conditioned medium {#Sec13}
---------------------------------

To generate conditioned medium from human 1%O~2~ MSCs (1%O~2~ hMSCs-CM) and human 21%O~2~ MSCs (21%O~2~ hMSCs-CM), human MSCs (3 × 10^5^ cells/dish) were seeded into 10-cm dishes and grown to 80% confluence. The culture medium was then substituted with DMEM containing 0.1% FBS, and the cells were cultured for 24 or 48 h under hypoxic (1% O~2~) or normoxic (21% O~2~) conditions. Then, each medium was collected.

Cell culture and treatments {#Sec14}
---------------------------

HK-2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured as described previously \[[@CR26]\]. After the starvation of HK-2 cells with conditioned medium from human MSCs or DMEM containing 0.1% FBS for 24 h, 10 ng/ml recombinant human TGF-β1 (R&D Systems, Minneapolis, MN, USA) was added to the cells directly. After 30 min (to investigate protein levels of p-Smad 2) or 48 h (to investigate protein levels of α-SMA), HK-2 cells were collected and subjected to in vitro study.

Counting MSCs {#Sec15}
-------------

Human MSCs (5 × 10^4^ cells/well) were seeded into six-well plates and grown to 60--80% confluence. The culture medium was then substituted with fresh DMEM containing 0.1% or 10% FBS, and the cells were cultured under hypoxic (1% O~2~) or normoxic (21% O~2~) conditions. The number of these cells was counted after 24 or 48 h.

Quantitative real-time reverse-transcription PCR {#Sec16}
------------------------------------------------

RNA extraction and real-time reverse-transcription PCR were performed in accordance with previously described methods \[[@CR26]\]. Specific oligonucleotide primers and probes for VEGF (assay ID Hs00900055_m1), HGF (assay ID Hs00300159_m1), and 18S rRNA (endogenous control) were obtained as TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA). The mRNA levels were standardized by the level of 18S rRNA.

ELISAs {#Sec17}
------

ELISA analyses of VEGF (R&D Systems), HGF (R&D Systems), and PGE2 (Enzo Life Science, Farmingdale, NY, USA) were performed following the manufacturers' protocols. Concentrations were normalized to the total protein content.

Transfection of VEGF siRNA {#Sec18}
--------------------------

Human MSCs were transfected with 20 nM siRNA targeting VEGF (sc-461; Applied Biosystems) or negative control siRNA (4390843; Applied Biosystems) using Lipofectamine 2000 Transfection Reagent (Thermo Fisher Scientific). After 24 h, the transfected cells were washed, and fresh complete medium was added. At 80% confluence, hypoxic preconditioning was performed. Then, the cells were collected and injected into the abdominal aorta. On the other hand, to generate conditioned medium from human 1%O~2~ MSCs transfected with VEGF siRNA or negative control siRNA, at 80% confluence, the transfected cells were cultured in DMEM containing 0.1% FBS for 48 h under hypoxic (1% O~2~) conditions. Then, each medium was collected.

Statistical analysis {#Sec19}
--------------------

Results are expressed as means ± standard deviations (S.D.). For multiple group comparisons, one-way ANOVA followed by Bonferroni's post hoc test was applied. Comparisons between two groups were analyzed by the Student's *t* test. *P* \< 0.05 was considered as statistically significant.

Results {#Sec20}
=======

Hypoxia-preconditioned rat MSCs attenuate IRI-induced renal fibrosis in rats {#Sec21}
----------------------------------------------------------------------------

To investigate the effect of hypoxia-preconditioned rat MSCs on renal fibrosis, we first examined the expression of α-SMA and TGF-β1 in the IRI model that had been injected with PBS, 5 × 10^5^ rat MSCs cultured under normoxic conditions (21%O~2~ rMSCs), or under 1% O~2~ conditions (1%O~2~ rMSCs) at 21 days post-IRI. As shown in Fig. [1](#Fig1){ref-type="fig"}a and b, protein levels of α-SMA and TGF-β1 were remarkably increased in IRI rats injected with PBS (PBS group). Such expression was suppressed in IRI rats injected with 21%O~2~ rMSCs (21%O~2~ rMSC group), and further suppression was observed in those injected with 1%O~2~ rMSCs (1%O~2~ rMSC group). Similarly, immunostaining revealed that the α-SMA-positive area was reduced in the 1%O~2~ rMSC group compared with the 21%O~2~ rMSC group (Fig. [1](#Fig1){ref-type="fig"}c, d). Furthermore, immunostaining revealed that collagen type I- and III-positive areas were more significantly suppressed in the 1%O~2~ rMSC group than in the 21%O~2~ rMSC group (Fig. [1](#Fig1){ref-type="fig"}c, d). Moreover, we performed HE staining at 7 and 21 days post-IRI. HE staining showed tubular dilatation, tubular cast formation, and diffused infiltration of inflammatory cells at 7 days post-IRI. These tubulointerstitial injuries were suppressed by the administration of 21%O~2~ rMSCs or 1%O~2~ rMSCs, with no significant difference between them (Additional file [1](#MOESM1){ref-type="media"}). Further progression of tubulointerstitial injuries and tubular atrophy were found at 21 days post-IRI. The progression of tubulointerstitial injuries and tubular atrophy were suppressed by the administration of 21%O~2~ rMSCs, and further suppression was observed in the 1%O~2~ rMSC group (Fig. [1](#Fig1){ref-type="fig"}e). Masson trichrome staining and Sirius red staining showed only slight interstitial fibrosis at 7 days post-IRI (Additional file [1](#MOESM1){ref-type="media"}), so we considered that the rat model at 7 days post-IRI was not suitable for evaluating the anti-fibrotic effect of MSCs. At 21 days post-IRI, further progression of interstitial fibrosis was observed in the PBS group and was attenuated by MSC treatment, particularly in the 1%O~2~ rMSC group (Fig. [1](#Fig1){ref-type="fig"}e, f). Fig. 11%O~2~ rMSCs suppress renal fibrosis more significantly than 21%O~2~ rMSCs in IRI rats. **a**, **b** Western blot analysis of α-SMA and TGF-β1 in the kidney cortex of IRI rats at day 21 post-IRI. Graphs show densitometric analyses of α-SMA and TGF-β1 expression levels normalized to the GAPDH expression level. **c** Representative immunohistochemical staining of α-SMA and collagen type I and III in kidney sections at day 21 post-IRI (scale bar = 100 μm). **d** Quantification of α-SMA- and collagen type I- and III-positive areas as percentages of the total area. **e** Representative images of HE, Masson trichrome, and Sirius red staining in kidney sections at day 21 post-IRI (scale bar = 100 μm). **f** Quantification of interstitial fibrosis area as percentages of the total area. Data are means ± S.D. ^\#^*P* \< 0.01 (one-way ANOVA followed by Bonferroni's post hoc test)

Hypoxia-preconditioned rat MSCs suppress the infiltration of inflammatory cells in IRI rats {#Sec22}
-------------------------------------------------------------------------------------------

To assess the anti-inflammatory effect of hypoxia-preconditioned rat MSCs, we examined the expression of CD3 (T cell marker), CD68 (M1 and M2 macrophage marker), and CD163 (M2 macrophage marker) at 7 days post-IRI. Immunohistochemical staining revealed that the accumulation of CD3- and CD68-positive cells was increased in the PBS group (Fig. [2](#Fig2){ref-type="fig"}a, b). The infiltration of these cells was suppressed in the 21%O~2~ rMSC group, whereas it was suppressed more significantly in the 1%O~2~ rMSC group (Fig. [2](#Fig2){ref-type="fig"}a, b). In contrast, the expression of CD163, an immunosuppressive macrophage marker, was increased in the 21%O~2~ rMSC group, and a further increase was observed in the 1%O~2~ rMSC group (Fig. [2](#Fig2){ref-type="fig"}a, b). In addition, we performed double immunostaining for CD68 and CD163 to identify M2 macrophages. Positive cells for both CD68 and CD163 were increased in the 21%O~2~ rMSC group, and a further increase was observed in the 1%O~2~ rMSC group (Fig. [2](#Fig2){ref-type="fig"}a, b). Fig. 21%O~2~ rMSCs attenuate renal inflammation more strongly than 21%O~2~ rMSCs in IRI rats. **a** Representative images of immunostaining of CD3, CD68, and CD163 and double immunostaining of CD163 (brown) and CD68 (blue) in the kidney sections at day 7 post-IRI (scale bar = 100 μm). **b** Quantification of CD3-, CD68-, and CD163-positive cells and double-positive (CD68 and CD163) cells. Data are means ± S.D. ^\#^*P* \< 0.01, \**P* \< 0.05 (one-way ANOVA followed by Bonferroni's post hoc test)

Hypoxia-preconditioned human MSCs also attenuate renal fibrosis in IRI rats {#Sec23}
---------------------------------------------------------------------------

To investigate whether hypoxia-preconditioned human MSCs also exerted therapeutic effects on renal fibrosis, we next injected PBS, 5 × 10^5^ human MSCs cultured under normoxic conditions (21%O~2~ hMSCs), or under 1% O~2~ conditions (1%O~2~ hMSCs) into the IRI model (21%O~2~ hMSC and 1%O~2~ hMSC groups, respectively). Although the upregulation of α-SMA and TGF-β1 in the PBS group was suppressed in the 21%O~2~ hMSC group, their expression in the 1%O~2~ hMSC group was reduced more significantly than in the 21%O~2~ hMSC group at 21 days post-IRI (Fig. [3](#Fig3){ref-type="fig"}a, b). Similarly, immunostaining revealed that the α-SMA-positive area was reduced in the 1%O~2~ hMSC group compared with the 21%O~2~ hMSC group (Fig. [3](#Fig3){ref-type="fig"}c, d). Furthermore, immunostaining revealed that collagen type I- and III-positive areas were more significantly suppressed in the 1%O~2~ hMSC group than in the 21%O~2~ hMSC group (Fig. [3](#Fig3){ref-type="fig"}c, d). Moreover, HE staining showed that tubulointerstitial injuries were more significantly suppressed in the 1%O~2~ hMSC group than in the 21%O~2~ hMSC group (Fig. [3](#Fig3){ref-type="fig"}e). Masson trichrome staining and Sirius red staining revealed that the area of interstitial fibrosis was reduced by MSC treatment, particularly in the 1%O~2~ hMSC group (Fig. [3](#Fig3){ref-type="fig"}e, f). Fig. 31%O~2~ hMSCs suppress renal fibrosis more significantly than 21%O~2~ hMSCs in IRI rats. **a**, **b** Western blot analysis of α-SMA and TGF-β1 in the kidney cortex of IRI rats at day 21 post-IRI. Graph shows densitometric analysis of α-SMA and TGF-β1 expression levels normalized to the GAPDH expression level. **c** Representative immunohistochemical staining of α-SMA and collagen type I and III in kidney sections at day 21 post-IRI (scale bar = 100 μm). **d** Quantification of α-SMA- and collagen type I- and III-positive areas as percentages of the total area. **e** Representative images of HE, Masson trichrome, and Sirius red staining in kidney sections at day 21 post-IRI (scale bar = 100 μm). **f** Quantification of interstitial fibrosis area as percentages of the total area. Data are means ± S.D. ^\#^*P* \< 0.01, \**P* \< 0.05 (one-way ANOVA followed by Bonferroni's post hoc test)

Hypoxic preconditioning does not change the immunophenotype of MSCs {#Sec24}
-------------------------------------------------------------------

It has been reported that the preconditioning of MSCs with hypoxia enhanced their migration capacity \[[@CR25], [@CR27]\]. Therefore, we studied whether hypoxic preconditioning enhances the engraftment capacity of MSCs using MSCs from male CAG-EGFP-transgenic SD rats. EGFP-positive cells were assessed as the average of ten randomly selected fields (× 100) for each rat at 21 days post-IRI (1%O~2~ rMSC group and 21%O~2~ rMSC group, *n* = 5). Immunohistochemical staining for EGFP revealed that the number of EGFP-positive cells was 10 ± 1 cells/10 fields in the 1%O~2~ rMSC group and 10 ± 1 cells/10 fields (× 100) in the 21%O~2~ rMSC group (Additional file 2a). These results suggest that hypoxic preconditioning does not increase the engraftment capacity of MSCs. In contrast, we found that anti-fibrotic ability was almost equal in 1%O~2~ rMSCs and 1%O~2~ hMSCs. Therefore, we investigated their engraftment using rMSCs from EGFP-transgenic rats and DiI-labeled hMSCs. EGFP-expressing rMSCs and DiI-labeled hMSCs were both observed in the kidney at day 21 post-IRI (Additional file [2](#MOESM2){ref-type="media"}a, b). Next, to assess whether hypoxic preconditioning affected their immunophenotype, we analyzed expression levels of cell surface markers using flow cytometry. Although human leukocyte antigen (HLA) expression plays an important role in the allogeneic immune response, the expression level of HLA-A,B,C did not differ between 21%O~2~ hMSCs and 1%O~2~ hMSCs (Additional file [3](#MOESM3){ref-type="media"}). Moreover, HLA-DR expression was not observed in both 21%O~2~ hMSCs and 1%O~2~ hMSCs (Additional file [3](#MOESM3){ref-type="media"}). Similarly, 21%O~2~ hMSCs and 1%O~2~ hMSCs expressed comparable levels of standard MSC markers, such as CD29, CD44, CD73, and CD90 (Additional file [3](#MOESM3){ref-type="media"}), and did not express MSC negative markers such as CD11b, CD34, and CD45 (Additional file [3](#MOESM3){ref-type="media"}).

Conditioned medium from hypoxia-preconditioned human MSCs suppresses fibrotic changes through inhibition of TGF-β/Smad signaling {#Sec25}
--------------------------------------------------------------------------------------------------------------------------------

To identify the direct effect of hypoxia-preconditioned MSCs on TGF-β/Smad signaling, we examined the expression of phosphorylated Smad2 and α-SMA in TGF-β1-stimulated HK-2 cells. We prepared 21%O~2~ hMSC-CM and 1%O~2~ hMSC-CM, and then stimulated HK-2 cells with TGF-β1 with and without each conditioned medium. The protein level of phosphorylated Smad2 was increased by TGF-β1 stimulation. The upregulation of phosphorylated Smad2 was more significantly suppressed by 1%O~2~ hMSC-CM than both normal medium and 21%O~2~ hMSC-CM (Fig. [4](#Fig4){ref-type="fig"}a). Similar results were observed for α-SMA protein expression (Fig. [4](#Fig4){ref-type="fig"}b). Fig. 4Conditioned medium from 1%O~2~ hMSCs inhibit TGF-β1-induced fibrotic changes in HK-2 cells strongly. **a** Western blot analysis of phosphorylated Smad2 (pSmad2) in HK-2 cells stimulated with TGF-β1 for 30 min. Graph shows densitometric analysis of the pSmad2 expression level normalized to the Smad2 expression level. **b** Western blot analysis of α-SMA in HK-2 cells stimulated with TGF-β1 for 48 h. Graph shows densitometric analysis of the α-SMA expression level normalized to the α-tubulin expression level. Data are means ± S.D. ^\#^*P* \< 0.01, \**P* \< 0.05 (one-way ANOVA followed by Bonferroni's post hoc test)

Hypoxia-preconditioned human MSCs enhance the production of VEGF, HGF, and PGE2 {#Sec26}
-------------------------------------------------------------------------------

MSCs reportedly secrete several humoral factors that promote tissue repair in a paracrine manner \[[@CR22], [@CR23]\]. To investigate whether hypoxia-preconditioned MSCs enhanced the secretion of these factors, we measured the concentrations of VEGF, HGF, and PGE2 in conditioned medium using ELISA kits. First, we confirmed that the numbers of both 1%O~2~ hMSCs and 21%O~2~ hMSCs were hardly increased because MSC-CM was obtained using 0.1% FBS-containing medium (Fig. [5](#Fig5){ref-type="fig"}a). As shown in Fig. [5](#Fig5){ref-type="fig"}b, we found upregulation of VEGF, HGF, and PGE2 in 1%O~2~ hMSC-CM compared with 21%O~2~ hMSC-CM. Next, we measured the expression levels of VEGF and HGF mRNA of hMSCs cultured with 10% FBS-containing medium. The number of 1%O~2~ hMSCs cultured with 10% FBS increased, as did that of 21% O~2~ hMSCs cultured with 10% FBS (Additional file [4](#MOESM4){ref-type="media"}a). In these conditions, we found upregulation of VEGF mRNA levels in the 1%O~2~ hMSCs compared with those in the 21%O~2~ hMSCs (Additional file [4](#MOESM4){ref-type="media"}b). However, there were no significant differences in the VEGF mRNA levels between hMSCs cultured under 1% O~2~ conditions for 24 h (1%O~2~ 24 h hMSCs) and 48 h (1%O~2~ 48 h hMSCs). Conversely, after both 24 and 48 h, there were no significant differences in HGF mRNA levels between 1%O~2~ hMSCs and 21%O~2~ hMSCs (Additional file [4](#MOESM4){ref-type="media"}c). Fig. 51%O~2~ hMSCs increase secretion of VEGF, HGF, and PGE2. **a** Graph showing the number of alive MSCs under normoxic conditions or 1% O~2~ conditions. Concentrations of vascular endothelial growth factor (VEGF) (**b**), hepatocyte growth factor (HGF) (**c**), and prostaglandin E2 (PGE2) (**d**) in each CM were measured using ELISA kits. Data are means ± S.D. ^\#^*P* \< 0.01, \**P* \< 0.05 (one-way ANOVA followed by Bonferroni's post hoc test)

Knockdown of VEGF in hypoxia-preconditioned human MSCs reduces the secretion of HGF and the anti-fibrotic effect in TGF-β1-stimulated HK-2 cells {#Sec27}
------------------------------------------------------------------------------------------------------------------------------------------------

The expression level of VEGF in 1%O~2~ hMSCs-CM was higher than in 21%O~2~ hMSCs-CM. Therefore, to assess whether VEGF in 1%O~2~ hMSCs-CM had an anti-fibrotic effect, we investigated 1%O~2~ hMSCs transfected with VEGF siRNA (VEGF siRNA/1%O~2~ hMSCs) or negative control siRNA (NC siRNA/1%O~2~ hMSCs). We confirmed the successful knockdown of VEGF in siRNA-transfected 1%O~2~ hMSCs by analyzing their conditioned medium (Fig. [6](#Fig6){ref-type="fig"}a). We next investigated the expression of HGF in the condition medium. As shown in Fig. [6](#Fig6){ref-type="fig"}b, ELISA analysis revealed that the expression of HGF was lower in conditioned medium from VEGF siRNA/1%O~2~ hMSCs (VEGF siRNA/1%O~2~ hMSC-CM) compared with that from NC siRNA/1%O~2~ hMSCs (NC siRNA/1%O~2~ hMSC-CM). Therefore, we examined whether VEGF was the upstream effector of HGF in hMSCs. As shown in Fig. [6](#Fig6){ref-type="fig"}c, we found that VEGF increased HGF expression after 72 h in a dose-dependent manner. Moreover, to elucidate the effect of VEGF on TGF-β1 signaling, we investigated the effect of NC siRNA/1%O~2~ hMSC-CM and VEGF siRNA/1%O~2~ hMSC-CM on α-SMA expression in TGF-β1-stimulated HK2 cells. NC siRNA/1%O~2~ hMSC-CM suppressed TGF-β1-induced the expression of α-SMA, whereas VEGF siRNA/1%O~2~ hMSC-CM attenuated this inhibitory effect (Fig. [6](#Fig6){ref-type="fig"}d). Fig. 6VEGF siRNA transfection of 1%O~2~ hMSCs attenuates inhibition of TGF-β1-induced fibrotic changes in HK-2 cells. 1%O~2~ hMSCs were transfected with VEGF siRNA (VEGF siRNA/1%O~2~ hMSCs) or negative control siRNA (NC siRNA/1%O~2~ hMSCs). Concentrations of VEGF (**a**) and HGF (**b**) were measured in CM from VEGF siRNA/1%O~2~ hMSCs and NC siRNA/1%O~2~ hMSCs using ELISA kits. **c** ELISA analysis showing the concentration of HGF in CM from 21%O~2~ hMSCs stimulated by VEGF at various concentrations (time, 72 h). **d** Western blot analysis of α-SMA in HK-2 cells stimulated with TGF-β1 for 48 h. Graph shows densitometric analysis of the α-SMA expression level normalized to the α-tubulin expression level. Data are means ± S.D. ^\#^*P* \< 0.01, \**P* \< 0.05 (one-way ANOVA followed by Bonferroni's post hoc test or Student's *t* test)

Knockdown of VEGF in hypoxia-preconditioned human MSCs reduces the anti-fibrotic effect in IRI rats {#Sec28}
---------------------------------------------------------------------------------------------------

To assess the effect of VEGF from 1%O~2~ hMSCs on renal fibrosis, we injected 1%O~2~ hMSCs transfected with VEGF siRNA or negative control siRNA into IRI rats (VEGF siRNA/1%O~2~ hMSC and NC siRNA/1%O~2~ hMSC groups, respectively). As shown in Fig. [7](#Fig7){ref-type="fig"}a and b, the protein levels of α-SMA and TGF-β1 were markedly increased in the PBS group and their upregulation was significantly inhibited in the NC siRNA/1%O~2~ hMSC group. However, their beneficial effect was weakened in the VEGF siRNA/1%O~2~ hMSC group. Immunostaining also revealed that the α-SMA-positive area was significantly reduced in the NC siRNA/1%O~2~ hMSC group, whereas it was decreased in the VEGF siRNA/1%O~2~ hMSC group (Fig. [7](#Fig7){ref-type="fig"}c, d). Similarly, collagen type I- and III-positive areas were markedly suppressed in the NC siRNA/1%O~2~ hMSC group, whereas the anti-fibrotic effect was reduced in the VEGF siRNA/1%O~2~ hMSC group (Fig. [7](#Fig7){ref-type="fig"}c, d). Fig. 7VEGF siRNA transfection attenuates the anti-fibrotic effect of 1%O~2~ hMSCs in IRI rats. **a**, **b** Western blot analysis of α-SMA and TGF-β1 in the kidney cortex of IRI rats at day 21 post-IRI. Graphs show densitometric analysis of α-SMA and TGF-β1 expression levels normalized to the GAPDH expression level. **c** Representative immunohistochemical staining of α-SMA and collagen type I and III in kidney sections at day 21 post-IRI (scale bar = 100 μm). **d** Quantification of α-SMA and collagen type I- and III-positive areas as percentages of the total area. Data are means ± S.D. ^\#^*P* \< 0.01 (one-way ANOVA followed by Bonferroni's post hoc test)

Discussion {#Sec29}
==========

This study has revealed that the administration of 1%O~2~ MSCs ameliorates renal fibrosis and inflammation in IRI rats. These beneficial effects are almost equivalent for rat- and human-derived bone marrow MSCs. In comparison with 21%O~2~ MSCs, 1%O~2~ MSCs further inhibited TGF-β/Smad signaling. Furthermore, 1%O~2~ MSCs enhanced VEGF secretion, whereas knockdown of VEGF reduced the anti-fibrotic effect of 1%O~2~ MSCs. These findings suggest that hypoxia-preconditioned MSCs enhance renoprotective effects by intensifying their paracrine abilities.

Previous studies have demonstrated that hypoxia-preconditioned MSCs attenuate tissue damage, which is mostly evaluated at the acute phase after tissue injury, but not at the chronic phase \[[@CR28]--[@CR30]\]. Pathologically, IRI induces acute tubular necrosis that follows the production of cytokines, including TGF-β1, which plays a major role in the progression of chronic renal damage \[[@CR14]--[@CR16]\]. These findings suggest that the therapeutic effects of 1%O~2~ MSCs are the result of ameliorating AKI. However, our data also showed that 1%O~2~ MSCs enhanced the ability to produce anti-fibrotic and anti-inflammatory humoral factors and that medium from 1%O~2~ MSCs inhibited TGF-β1-induced fibrotic changes. Moreover, we found that MSCs existed in the kidney at 21 days after IRI. Taken together, hypoxia-preconditioned MSCs confer the ability to suppress chronic tissue damage after AKI.

As a mechanism by which MSCs exert an anti-fibrotic effect, we previously found that conditioned medium from MSCs inhibits TGF-β/Smad signaling \[[@CR31]\]. The presenting data showed that conditioned medium from 1%O~2~ MSCs further suppressed TGF-β1-induced phosphorylation of Smad2 and α-SMA in HK-2 cells compared with 21%O~2~ MSCs. In terms of inflammation, we found that 1%O~2~ MSCs enhanced immunosuppressive abilities in IRI rats. Among humoral factors, PGE2 is reportedly secreted from MSCs, playing an important role in changing the phenotype of macrophages from proinflammatory M1 to immunosuppressive M2 \[[@CR32]\]. Indeed, we demonstrated that 1%O~2~ MSCs enhanced PGE2 secretion and that the administration of 1%O~2~ MSCs not only suppressed the infiltration of inflammatory cells, but also increased M2 macrophages in IRI rats. Considering that chronic inflammation is well recognized to participate in the progression of renal fibrosis \[[@CR11], [@CR14]--[@CR16]\], these results suggest that, in addition to the inhibition of TGF-β/Smad signaling, the enhanced immunosuppressive abilities of hypoxia-preconditioned MSCs are involved in both anti-inflammatory and anti-fibrotic effects.

We demonstrated that 1%O~2~ MSCs promoted the production of VEGF and that VEGF knockdown reduced the anti-fibrotic effect in IRI rats. To adapt to hypoxic conditions, the upregulation of hypoxia-inducible factor is responsible for gene expression of VEGF, erythropoietin, and glucose transporter 1 \[[@CR33]--[@CR35]\]. Several studies have reported that VEGF functions as a renoprotective humoral factor \[[@CR36]--[@CR38]\], with evidence indicating that the administration of VEGF suppresses renal fibrosis \[[@CR39]\]. These findings suggest that the upregulation of VEGF is implicated in the anti-fibrotic effect of 1%O~2~ MSCs. Interestingly, we identified HGF as a downstream effector of VEGF in 1%O~2~ MSCs. Previous studies have shown that HGF is a potent anti-fibrotic cytokine that antagonizes TGF-β/Smad signaling \[[@CR40], [@CR41]\]. Moreover, we previously found that a HGF-neutralizing antibody diminishes the anti-fibrotic effect of MSCs \[[@CR31]\]. These results suggest that 1%O~2~ MSCs enhance HGF secretion through the upregulation of VEGF, leading to their anti-fibrotic effect. In this study, we observed that HGF mRNA levels were almost equal in 1%O~2~ hMSCs and 21%O~2~ hMSCs. Nevertheless, 1%O~2~ hMSCs showed enhanced HGF secretion. Previous studies also showed that hypoxic preconditioning enhanced HGF secretion from bone marrow-derived MSCs \[[@CR24], [@CR42]\]. In contrast, two recent studies reported that hypoxia-preconditioned adipose-derived MSCs exhibited a reduction of such secretion \[[@CR43], [@CR44]\]. These differences may be attributable to the tissues from which the MSCs were derived.

It has been reported that MSCs are characterized by the low expression of major histocompatibility complex (MHC) class I and no expression of MHC class II. Therefore, MSCs do not activate allogeneic lymphocytes \[[@CR45]\]. Recent studies have reported that MSCs preconditioned by several inflammatory cytokines have therapeutic effects \[[@CR46]--[@CR48]\]. However, according to other studies, some cytokines upregulate MHC expression levels in MSCs, thereby elevating their immunogenicity \[[@CR49], [@CR50]\]. These findings raise the possibility that cytokine-preconditioned MSCs cause allogeneic immune rejection in transplantation. In this study, 1%O~2~ MSCs did not change HLA expression. AKI often occurs within a few hours or a day, and it is impossible to prepare autologous MSCs beforehand for therapy. Therefore, we attempted to demonstrate that allogeneic hypoxia-preconditioned MSC transplantation is available for treating AKI to CKD progression. For the clinical application of human MSCs, we needed to investigate whether hypoxic preconditioning enhances the anti-fibrotic ability of human MSCs to the same extent as rat MSCs, so we administered not only 1%O~2~ rMSCs, but also 1%O~2~ hMSCs to a rat IRI model. Actually, we observed that the anti-fibrotic effect of 1%O~2~ MSCs was almost equivalent in MSCs derived from rats and humans. Moreover, rat- and human-derived MSCs administered through the abdominal aorta were both observed in the kidney at day 21 post-IRI. These results suggest that hypoxia-preconditioned human MSCs have low immunogenicity and may be a good candidate for cell therapy by allogeneic transplantation. Meanwhile, Avivar-Valderas et al. reported that patients showing preexisting immunity were prone to generating donor-specific antibodies (DSA) when they were administered with allogeneic adipose MSCs. Their results suggest that sensitization may be a significant concern when patients are receiving re-treatment or multi-donor trials, although DSA generation did not correlate with MSC therapeutic efficacy \[[@CR51]\]. Our study suggests that initial allogeneic hypoxia-preconditioned MSC transplantation has the potential to be a useful therapy for preventing the progression of AKI to CKD. However, further studies are needed to determine whether re-administration of allogeneic MSCs is available for treating AKI to CKD progression.

Conclusions {#Sec30}
===========

In summary, the administration of 1%O~2~ MSCs significantly ameliorated renal fibrosis and inflammation in IRI rats compared with 21%O~2~ MSCs. We also found that 1%O~2~ MSCs confer the ability to upregulate humoral factors including VEGF, HGF, and PGE2. Among them, VEGF plays an important role in not only HGF production, but also the 1%O~2~ MSC-mediated anti-fibrotic effect. Our results indicate that hypoxia-preconditioned MSCs are useful as a cell therapy by allogeneic transplantation to prevent progression of AKI to CKD.
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**Additional file 1.** Only slight interstitial fibrosis occurs at 7 days post-IRI. Representative images of HE, Masson trichrome, and Sirius red staining in kidney sections at 7 days post-IRI (scale bar = 100 μm). **Additional file 2.**Human and rat MSCs localize in the kidney by day 21 post-IRI. MSCs collected from enhanced green fluorescent protein (EGFP)-expressing rats or DiI-labeled human MSCs were injected through the abdominal aorta after reperfusion. **a** Representative immunohistochemical staining of EGFP-positive cells (arrows) in the kidney cortex at 21 days post-IRI (scale bar = 100 μm). **b** Representative images showing DiI-labeled human MSCs (arrowheads; scale bar = 100 μm). The right panel shows periodic acid-Schiff (PAS) staining in the same tissue section (scale bar = 100 μm). **Additional file 3.** Hypoxic preconditioning does not change expression of MSC surface markers. Flow cytometry showing expression of surface markers on 21%O~2~ hMSCs and 1%O~2~ hMSCs. **Additional file 4.**1%O~2~ hMSCs increase the expression of VEGF mRNA, but not HGF mRNA. **a** Graph showing the number of alive MSCs cultured in medium containing 10% FBS under normoxic conditions or 1% O~2~ conditions. VEGF (**b**) and HGF (**d**) mRNA expression levels of MSCs were measured by PCR analysis. Data are means ± S.D. ^\#^*P* \< 0.01, \**P* \< 0.05 (one-way ANOVA followed by Bonferroni's post-hoc test or Student's t-test).

AKI

:   Acute kidney injury

CKD

:   Chronic kidney disease

CM

:   Conditioned medium

EGFP

:   Enhanced green fluorescent protein

EMT

:   Epithelial-mesenchymal transition

HGF

:   Hepatocyte growth factor

HLA

:   Human leukocyte antigen

IRI

:   Ischemia-reperfusion injury

MHC

:   Major histocompatibility complex

MSC

:   Mesenchymal stem cells

1%O~2~ MSCs

:   MSCs cultured under 1% O~2~ conditions

21%O~2~ MSCs

:   MSCs cultured under normoxic conditions

1%O~2~ hMSCs

:   Human MSCs cultured under 1% O~2~ conditions

1%O~2~ hMSCs-CM

:   Conditioned medium from human 1%O~2~ MSCs

21%O~2~ hMSCs

:   Human MSCs cultured under normoxic conditions

21%O~2~ hMSCs-CM

:   Conditioned medium from human 21%O~2~ MSCs

1%O~2~ rMSCs

:   Rat MSCs cultured under 1% O~2~ conditions

21%O~2~ rMSCs

:   Rat MSCs cultured under normoxic conditions

NC siRNA/1%O~2~ hMSCs

:   1%O~2~ hMSCs transfected with negative control siRNA

NC siRNA/1%O~2~ hMSC-CM

:   Conditioned medium from NC siRNA/1%O~2~ hMSCs

PGE2

:   Prostaglandin E2

SD

:   Sprague-Dawley

TGF

:   Transforming growth factor

VEGF

:   Vascular endothelial growth factor

VEGF siRNA/1%O~2~ hMSCs

:   1%O~2~ hMSCs transfected with VEGF siRNA

VEGF siRNA/1%O~2~ hMSC-CM

:   Conditioned medium from VEGF siRNA/1%O~2~ hMSCs
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